Enveric Biosciences Begins Genotoxicity Testing for EB-003

▤ Summary

Enveric Biosciences says it has begun genotoxicity testing for EB-003, moving the program further through preclinical development. The announcement signals progress on safety evaluation for the candidate before any later-stage regulatory or clinical steps. The available text does not include the underlying study details because the article page is inaccessible. Even so, the title indicates a routine but important research milestone for a life sciences software and services audience tracking pharma development activity.

▦ Linked Companies